Get the Weekly Intelligence Brief — top committee picks every Sunday.
LQDA · NASDAQ · STOCK

Liquidia (LQDA) Stock Analysis

Healthcare Updated October 10, 2026
$27.39
52W $21.94 – $93.61
50/100
$2.43B
17.4
0.54
AI Committee Verdict
Watch
50/100
Conviction: Contested · 33% agreement · 6 analysts
+9.0%
-22.8%
0.39:1
Contested

Is LQDA Bullish or Bearish?

Mixed. Innellis AI committee rates Liquidia Corporation (LQDA) Watch with a composite score of 50/100 , based on 6 analysts with 33% agreement. Last updated October 10, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +10.00 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -10.00 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Macro Analyst sees a compelling case. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • ROE of 149.6% shows genuine earnings power backing the valuation — Value
  • Revenue growing 2233.7% YoY -- genuine top-line momentum — Growth
Bear Case
  • Price-to-book of 12.9x prices in significant intangible value — Value
  • Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
  • RSI at 20 is in oversold territory (could mean either capitulation or a bounce setup) — Technical
  • MACD histogram negative -- bearish momentum — Technical
  • Weekly RSI at 16 -- oversold on the larger timeframe too — Technical
  • Bollinger bandwidth of 157.3% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of October 10, 2026
Overall Committee Score
50/100
Agreement
33%
Analysts
6
Conviction
Contested
Sector Rank
Top 94%
of 192 Healthcare peers
Value Analyst neutral
55 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 149.6% shows genuine earnings power backing the valuation
− Price-to-book of 12.9x prices in significant intangible value
Growth Analyst bullish
60 / 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 2233.7% YoY -- genuine top-line momentum
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst bearish
38 / 100 · High confidence
Price action is deteriorating -- trend and/or momentum are working against this name
− RSI at 20 is in oversold territory (could mean either capitulation or a bounce setup)
Risk Analyst bearish
35 / 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 157.3% signals elevated volatility
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst neutral
47 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
− News sentiment is negative (-0.33 across 44 articles, 14d)
Portfolio Manager bearish
30 / 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 50.0 to 50.0.

Analyst-level changes:
  • Risk Analyst: +1 bearish signal(s).

Comparing 2026-10-09 to 2026-10-10 (1 day apart).

Technical Analysis

RSI (14)
19.6
Oversold
MACD Histogram
-3.041
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Mixed
Support
$21.14
Resistance
$29.84
Bollinger %B
0.20
Inside Bands
Price vs Moving Averages
EMA 9
$34.58 Below
EMA 21
$47.27 Below
EMA 50
$59.34 Below
EMA 200
$55.07 Below

Fundamental Analysis

Valuation
63
Growth
62
Profitability
50
Financial Health
96
Cash Flow
70
Valuation
P/E Ratio 17.4×
P/B Ratio 12.47×
PEG Ratio 0.01
Dividend Yield 0.00%
52W High $93.61
52W Low $21.94
Quality & Growth
ROE -15402.7%
ROA -2101.8%
Gross Margin 9247.6%
Operating Margin 3738.6%
Revenue Growth YoY —
Debt / Equity 0.66
AI Fundamental Assessment
P/E ratio of 17.4 (inexpensive relative to a 15-40x range); Price-to-book of 12.5x; PEG ratio of 0.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -154.0%; Return on assets of -21.0%; Net margin of 30.7%; Gross margin of 92.5%; Current ratio of 2.31 (healthy short-term liquidity); Debt-to-equity of 0.66; Free cash flow per share is positive (0.68); Most recent quarter missed estimates by 2.3%; EPS growth decelerating (+205.9% -> +42.3% QoQ); Average YoY EPS growth of 251.0%; Analyst estimates rising over recent quarters
Get the Full LQDA Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime